Your browser doesn't support javascript.
loading
Psychometric validation of the German version of the EPIC-26 questionnaire for patients with localized and locally advanced prostate cancer.
Sibert, Nora Tabea; Dieng, Sebastian; Oesterle, Alisa; Feick, Günter; Carl, Günther; Steiner, Thomas; Minner, Jörg; Roghmann, Florian; Kaftan, Björn; Zengerling, Friedemann; Hinkel, Andreas; Beyer, Burkhard; Heidenreich, Axel; Harke, Nina; Brehmer, Bernhard; Pfitzenmaier, Jesco; Fichtner, Jan; Neisius, Andreas; Hammerer, Peter; Wesselmann, Simone; Kowalski, Christoph.
Afiliação
  • Sibert NT; German Cancer Society, Kuno-Fischer-Strasse 8, Berlin, 14057, Germany. sibert@krebsgesellschaft.de.
  • Dieng S; OnkoZert, Neu-Ulm, Germany.
  • Oesterle A; OnkoZert, Neu-Ulm, Germany.
  • Feick G; Federal Association of German Prostate Cancer Patient Support Groups, Bonn, Germany.
  • Carl G; Help for Prostate Cancer Patients (Förderverein Hilfe bei Prostatakrebs e.V.-FHbP), Tornesch, Germany.
  • Steiner T; Helios Klinikum Erfurt, Erfurt, Germany.
  • Minner J; Hegau-Bodensee-Klinikum Singen, Singen, Germany.
  • Roghmann F; Marien Hospital, Ruhr-University Bochum, Herne, Germany.
  • Kaftan B; Städtisches Klinikum Lüneburg, Lüneburg, Germany.
  • Zengerling F; Universitätsklinikum Ulm, Ulm, Germany.
  • Hinkel A; Franziskus Hospital, Bielefeld, Germany.
  • Beyer B; Martini-Klinik Prostate Cancer Center Hamburg, Hamburg, Germany.
  • Heidenreich A; Universitätsklinikum Köln, Cologne, Germany.
  • Harke N; University Hospital Essen, Essen, Germany.
  • Brehmer B; Diaconal Hospital of Schwäbisch Hall, Schwäbisch Hall, Germany.
  • Pfitzenmaier J; Evangelisches Klinikum Bethel Johannesstift, Bielefeld, Germany.
  • Fichtner J; Johanniter Krankenhaus Oberhausen, Oberhausen, Germany.
  • Neisius A; Barmherzige Brüder Trier, Trier, Germany.
  • Hammerer P; Städtisches Klinikum Braunschweig, Brunswick, Germany.
  • Wesselmann S; German Cancer Society, Kuno-Fischer-Strasse 8, Berlin, 14057, Germany.
  • Kowalski C; German Cancer Society, Kuno-Fischer-Strasse 8, Berlin, 14057, Germany.
World J Urol ; 39(1): 11-25, 2021 Jan.
Article em En | MEDLINE | ID: mdl-31552467
ABSTRACT

PURPOSE:

For patients with prostate cancer, validated and reliable instruments are essential for measuring patient-reported outcomes. The aim of this study was to validate the German version of the widely established Expanded Prostate Cancer Index Composite with 26 items (EPIC-26).

METHODS:

A German translation of the original questionnaire was tested in 3094 patients with localized or locally advanced (any T, any N and M0) prostate cancer with treatment intent (including radical prostatectomy, brachytherapy, active surveillance, watchful waiting). They completed the EPIC-26 questionnaire before treatment. A total of 521 of them also completed a questionnaire 12 months afterward. Internal consistency, sensitivity to change, and construct validity were assessed.

RESULTS:

The internal consistency of all domains was sufficient (Cronbach's alpha between 0.64 and 0.93). Item-to-scale correlation coefficients showed acceptable associations between items and their domain score (all > 0.30), with the lowest scores for "bloody stools" (r = 0.37) and "breast problems" (r = 0.32). Confirmatory and exploratory factor analysis confirmed the five-dimension structure of the EPIC-26 (comparative fit index 0.95).

CONCLUSIONS:

Psychometric evaluation suggests that the German version of the EPIC-26 is a well-constructed instrument for measuring patient-reported health-related symptoms in patients with prostate cancer.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Psicometria / Medidas de Resultados Relatados pelo Paciente Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Psicometria / Medidas de Resultados Relatados pelo Paciente Idioma: En Ano de publicação: 2021 Tipo de documento: Article